Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma
Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA seque...
Gespeichert in:
| Veröffentlicht in: | PLoS genetics Jg. 21; H. 10; S. e1011848 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Public Library of Science (PLoS)
01.10.2025
|
| Schlagworte: | |
| ISSN: | 1553-7404, 1553-7390, 1553-7404 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME.
Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018. |
|---|---|
| AbstractList | Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME. Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018. Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME. Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018.Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME. Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018. Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME. Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018. |
| Author | Ellis, Jenna-Claire Caers, Jo Köse, Murat Cem Van Houdt, Jeroen Fourneau, Nele Heidrich, Bradley Heuck, Christoph J. Vlummens, Philip Verona, Raluca Delforge, Michel Van Droogenbroeck, Jan Beguin, Yves Bahlis, Nizar Casneuf, Tineke Kurth, William Vanhoof, Greet De Maeyer, Dries Meuleman, Nathalie Smets, Tina Verbist, Bie Bergiers, Isabelle Skerget, Sheri Malfait, Milan Van der Borght, Koen |
| Author_xml | – sequence: 1 givenname: Isabelle orcidid: 0000-0001-9622-7960 surname: Bergiers fullname: Bergiers, Isabelle – sequence: 2 givenname: Murat Cem orcidid: 0009-0002-9352-9909 surname: Köse fullname: Köse, Murat Cem – sequence: 3 givenname: Sheri surname: Skerget fullname: Skerget, Sheri – sequence: 4 givenname: Milan orcidid: 0000-0001-9144-3701 surname: Malfait fullname: Malfait, Milan – sequence: 5 givenname: Nele orcidid: 0009-0000-9329-0649 surname: Fourneau fullname: Fourneau, Nele – sequence: 6 givenname: Jenna-Claire orcidid: 0009-0009-5914-9188 surname: Ellis fullname: Ellis, Jenna-Claire – sequence: 7 givenname: Greet surname: Vanhoof fullname: Vanhoof, Greet – sequence: 8 givenname: Tina surname: Smets fullname: Smets, Tina – sequence: 9 givenname: Bie surname: Verbist fullname: Verbist, Bie – sequence: 10 givenname: Dries orcidid: 0000-0002-1314-3348 surname: De Maeyer fullname: De Maeyer, Dries – sequence: 11 givenname: Jeroen surname: Van Houdt fullname: Van Houdt, Jeroen – sequence: 12 givenname: Koen surname: Van der Borght fullname: Van der Borght, Koen – sequence: 13 givenname: Raluca surname: Verona fullname: Verona, Raluca – sequence: 14 givenname: Bradley surname: Heidrich fullname: Heidrich, Bradley – sequence: 15 givenname: William surname: Kurth fullname: Kurth, William – sequence: 16 givenname: Michel surname: Delforge fullname: Delforge, Michel – sequence: 17 givenname: Nathalie surname: Meuleman fullname: Meuleman, Nathalie – sequence: 18 givenname: Jan surname: Van Droogenbroeck fullname: Van Droogenbroeck, Jan – sequence: 19 givenname: Philip surname: Vlummens fullname: Vlummens, Philip – sequence: 20 givenname: Christoph J. surname: Heuck fullname: Heuck, Christoph J. – sequence: 21 givenname: Yves surname: Beguin fullname: Beguin, Yves – sequence: 22 givenname: Nizar orcidid: 0000-0001-7353-7034 surname: Bahlis fullname: Bahlis, Nizar – sequence: 23 givenname: Tineke surname: Casneuf fullname: Casneuf, Tineke – sequence: 24 givenname: Jo orcidid: 0000-0002-3175-1195 surname: Caers fullname: Caers, Jo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41056512$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkU9v1DAQxS1URP_AN0AoRy672LEd20dUUVipUi9wtmbtSdar2A52grTfnpRdqp5mNPrNG817t-Qq5YSEfGR0y7hiX455KQnG7TRg2jLKmBb6DblhUvKNElRcveqvyW2tR0q51Ea9I9eCUdlJ1t6QYRfjkvJ0wJTn0xRc4w6QBqxNSM18wGZeYi4NJH_pYnAlY_oTSk4R09z4pYQ0NFPJQ8FaQ173chOXcQ7TiE084ZgjvCdvexgrfrjUO_Lr4dvP-x-bx6fvu_uvjxvHFZ03nAkHCK2AvqeKsc5T7SRo7qA33qByzKgWO4eATO8dl-hMvzfO-5btpeF3ZHfW9RmOdiohQjnZDMH-G-QyWChzcCNar3XX9YyDok6AYNB5kMoAGKM7ofWq9fmstf72e8E62xiqw3GEhHmplrdSrzZSrVb00wVd9hH9y-H_Rq-AOAOre7UW7F8QRu1znvaSp33O017y5H8BQPGZZw |
| Cites_doi | 10.1038/s41375-018-0036-x 10.1096/fj.06-6610com 10.3390/ijms23147627 10.1111/j.1365-2141.2005.05507.x 10.3390/ijms22073490 10.3390/biomedicines3010071 10.1038/s41467-020-19894-4 10.4049/jimmunol.167.1.49 10.1038/s41591-018-0269-2 10.1038/s41375-019-0404-1 10.1016/j.lfs.2014.11.011 10.1111/j.1365-2249.2006.03037.x 10.3389/fonc.2021.694331 10.3390/cancers12071791 10.1016/S1074-7613(03)00208-5 10.1182/blood-2003-06-2043 10.1182/blood-2023-173550 10.1038/s41598-019-41695-z 10.1038/s41568-019-0235-4 10.1182/bloodadvances.2022007217 10.1038/s41379-018-0011-0 10.1182/blood.2020005795 10.1158/1541-7786.MCR-19-0487 10.1038/s41467-021-22804-x 10.1016/j.immuni.2007.09.006 10.1038/bonekey.2016.14 10.1182/blood-2023-187755 10.3390/cancers9040035 10.1016/S0140-6736(21)00135-5 10.1093/bioinformatics/btr260 10.3390/cancers12010173 10.1038/nmeth.4380 10.1182/blood.V100.1.230 10.1016/j.diff.2016.11.005 10.1016/S1470-2045(14)70442-5 10.1016/j.omtn.2021.10.011 10.3390/ijms22073389 10.1080/10428194.2020.1827253 10.1038/s41590-021-00931-3 10.1038/s41592-019-0619-0 10.1186/s13045-016-0345-3 10.1016/j.actbio.2021.04.052 10.1038/nbt.3192 10.1038/s41588-025-02196-0 10.1186/s13059-017-1382-0 10.1101/gr.192237.115 10.3390/jcm10163717 10.3390/cancers11040529 10.1038/s41577-019-0221-9 10.1038/cddis.2017.533 10.1517/13543784.2013.740010 10.1002/ajh.26590 10.1200/JCO.20.00437 10.1155/2013/183602 10.1093/jnci/djw131 10.18632/oncotarget.5025 10.1038/s41590-021-00961-x 10.1038/s41375-020-01051-x 10.1074/jbc.REV119.007759 10.1073/pnas.202491499 10.1038/bcj.2015.3 10.1038/s41467-022-33944-z 10.1038/s41588-024-01853-0 10.1038/s43018-020-0053-3 10.1186/s40425-019-0551-y 10.1038/s41525-022-00340-x 10.1007/s12032-009-9230-z 10.1038/s41467-021-22140-0 10.1016/j.bbmt.2011.03.011 10.1038/s41467-022-30694-w 10.1158/2326-6066.CIR-15-0178 10.1038/s41573-022-00520-5 10.1073/pnas.0305855101 10.1182/blood-2016-01-695395 10.1111/ejh.12774 10.1101/2023.06.13.544751 10.1182/blood-2018-01-825265 10.1186/s40164-022-00267-0 10.1084/jem.191.6.1077 10.1182/blood-2003-06-1984 10.1182/blood-2015-01-623975 10.1007/s10456-010-9163-3 10.1186/s40164-017-0081-6 10.4049/jimmunol.180.6.3655 10.1182/blood-2005-11-013458 10.1016/j.cellsig.2020.109672 10.1016/j.intimp.2020.107318 10.3390/ijms23020904 10.4068/cmj.2015.51.1.1 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2025 Bergiers et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| Copyright_xml | – notice: Copyright: © 2025 Bergiers et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
| DOI | 10.1371/journal.pgen.1011848 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ: Directory of Open Access Journal (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1553-7404 |
| ExternalDocumentID | oai_doaj_org_article_d8866f13a70c4a41a6da579aa9986488 41056512 10_1371_journal_pgen_1011848 |
| Genre | Journal Article |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAUCC AAWOE AAYXX ABDBF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AFFHD AFKRA AFPKN AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS B0M BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BHPHI BPHCQ BVXVI BWKFM CCPQU CITATION CS3 DIK DU5 E3Z EAP EAS EBD EBS EJD EMK EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IGS IHR IHW INH INR IOV ISN ISR ITC KQ8 LK8 M1P M7P O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PV9 QF4 QN7 RNS RPM RZL SV3 TR2 TUS UKHRP WOW XSB ~8M ADRAZ C1A CGR CUY CVF ECM EIF H13 IPNFZ M48 NPM RIG WOQ 7X8 |
| ID | FETCH-LOGICAL-c370t-314caea24aff07116d08c5a83caf9d9e7c1972e6ceae18bc35ec9fb9cdd21b593 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001588430800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1553-7404 1553-7390 |
| IngestDate | Mon Nov 03 21:53:56 EST 2025 Thu Oct 09 00:13:47 EDT 2025 Thu Oct 30 01:58:53 EDT 2025 Wed Oct 29 21:23:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | Copyright: © 2025 Bergiers et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c370t-314caea24aff07116d08c5a83caf9d9e7c1972e6ceae18bc35ec9fb9cdd21b593 |
| Notes | new_version ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-7353-7034 0009-0002-9352-9909 0009-0000-9329-0649 0000-0002-1314-3348 0009-0009-5914-9188 0000-0001-9622-7960 0000-0002-3175-1195 0000-0001-9144-3701 |
| OpenAccessLink | https://doaj.org/article/d8866f13a70c4a41a6da579aa9986488 |
| PMID | 41056512 |
| PQID | 3258565087 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d8866f13a70c4a41a6da579aa9986488 proquest_miscellaneous_3258565087 pubmed_primary_41056512 crossref_primary_10_1371_journal_pgen_1011848 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-10-01 |
| PublicationDateYYYYMMDD | 2025-10-01 |
| PublicationDate_xml | – month: 10 year: 2025 text: 2025-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | PLoS genetics |
| PublicationTitleAlternate | PLoS Genet |
| PublicationYear | 2025 |
| Publisher | Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science (PLoS) |
| References | A Mikulasova (pgen.1011848.ref029) 2016; 97 I Korsunsky (pgen.1011848.ref095) 2019; 16 O Beyar-Katz (pgen.1011848.ref058) 2019; 17 G Jego (pgen.1011848.ref042) 2003; 19 M Ho (pgen.1011848.ref007) 2020; 34 MJ Benson (pgen.1011848.ref034) 2008; 180 A Liberzon (pgen.1011848.ref099) 2011; 27 H van Andel (pgen.1011848.ref024) 2019; 33 FA Wolf (pgen.1011848.ref090) 2018; 19 AM van der Leun (pgen.1011848.ref044) 2020; 20 AL Doedens (pgen.1011848.ref076) 2016; 4 M-D Hoang (pgen.1011848.ref064) 2015; 51 M Yan (pgen.1011848.ref033) 2021; 26 X Zhang (pgen.1011848.ref083) 2001; 167 M Bustoros (pgen.1011848.ref011) 2020; 38 G Ledergor (pgen.1011848.ref014) 2018; 24 R Boiarsky (pgen.1011848.ref018) 2022; 13 L Deng (pgen.1011848.ref037) 2010; 1806 AA Sergushichev (pgen.1011848.ref100) 2016 S Berardi (pgen.1011848.ref052) 2013; 2013 R Satija (pgen.1011848.ref092) 2015; 33 BY Owusu (pgen.1011848.ref080) 2017; 9 A Gutiérrez-González (pgen.1011848.ref073) 2016; 128 PJ Hengeveld (pgen.1011848.ref054) 2015; 5 M Stoeckius (pgen.1011848.ref094) 2017; 14 C Zelle-Rieser (pgen.1011848.ref048) 2016; 9 B Vasir (pgen.1011848.ref069) 2005; 129 CU Blank (pgen.1011848.ref030) 2019; 19 JA Määttä (pgen.1011848.ref085) 2016; 5 Q Gao (pgen.1011848.ref027) 2018; 31 NWCJ van de Donk (pgen.1011848.ref006) 2021; 397 pgen.1011848.ref050 G Bianchi (pgen.1011848.ref001) 2014; 64 MME de Jong (pgen.1011848.ref017) 2021; 22 W Pilcher (pgen.1011848.ref049) 2023; 8 J Tan (pgen.1011848.ref047) 2018; 14 pgen.1011848.ref051 J Moreaux (pgen.1011848.ref056) 2004; 103 SL Wolock (pgen.1011848.ref091) 2019; 8 M Bustoros (pgen.1011848.ref010) 2022; 13 M Colombo (pgen.1011848.ref023) 2015; 6 F Fercoq (pgen.1011848.ref028) 2021; 22 Y Zhao (pgen.1011848.ref031) 2022; 11 F Zhan (pgen.1011848.ref008) 2006; 108 E Verheye (pgen.1011848.ref066) 2022; 23 K Mahtouk (pgen.1011848.ref079) 2010; 1806 J-B Alberge (pgen.1011848.ref013) 2025; 57 J Chen (pgen.1011848.ref059) 2017; 8 L McInnes (pgen.1011848.ref096) 2018 E Terpos (pgen.1011848.ref087) 2017; 26 pgen.1011848.ref101 MS Kowalczyk (pgen.1011848.ref093) 2015; 25 L Rao (pgen.1011848.ref040) 2020; 12 J Sun (pgen.1011848.ref053) 2022; 10 O Zavidij (pgen.1011848.ref015) 2020; 1 T Tohami (pgen.1011848.ref026) 2007; 21 P Neumeister (pgen.1011848.ref004) 2022; 23 Q Wang (pgen.1011848.ref074) 2020; 136 WHD Hallett (pgen.1011848.ref046) 2011; 17 C Schlundt (pgen.1011848.ref061) 2021; 133 WC Pilcher (pgen.1011848.ref102) 2024 M Janiszewska (pgen.1011848.ref088) 2020; 295 SM Abdelmagid (pgen.1011848.ref060) 2015; 123 AJ Novak (pgen.1011848.ref035) 2004; 103 M Braunlin (pgen.1011848.ref003) 2021; 62 PWB Derksen (pgen.1011848.ref022) 2004; 101 L Soumoy (pgen.1011848.ref071) 2019; 11 SV Rajkumar (pgen.1011848.ref005) 2022; 97 W Li (pgen.1011848.ref055) 2010; 27 SV Rajkumar (pgen.1011848.ref089) 2014; 15 pgen.1011848.ref002 J Xu (pgen.1011848.ref072) 2021; 11 A Spina (pgen.1011848.ref081) 2015; 3 HL Crowell (pgen.1011848.ref098) 2020; 11 T-N Nguyen-Pham (pgen.1011848.ref065) 2012; 2012 D Rizzieri (pgen.1011848.ref021) 2019; 5 J Korbecki (pgen.1011848.ref038) 2021; 22 R Liu (pgen.1011848.ref019) 2021; 12 C Guillerey (pgen.1011848.ref045) 2018; 132 MK Brimnes (pgen.1011848.ref062) 2006; 144 J Delli Carpini (pgen.1011848.ref039) 2010; 13 MV Dhodapkar (pgen.1011848.ref067) 2002; 99 KM Knudson (pgen.1011848.ref077) 2019; 7 A Bendre (pgen.1011848.ref084) 2017; 93 J-S Du (pgen.1011848.ref086) 2021; 22 M Ratta (pgen.1011848.ref063) 2002; 100 A Knight (pgen.1011848.ref043) 2021; 10 L Zhang (pgen.1011848.ref041) 2017; 6 S Zhang (pgen.1011848.ref078) 2021; 91 A Mantovani (pgen.1011848.ref057) 2022; 21 LK Ashman (pgen.1011848.ref025) 2013; 22 Y Zheng (pgen.1011848.ref075) 2016; 108 C Schinke (pgen.1011848.ref016) 2022; 6 P Leone (pgen.1011848.ref068) 2015; 126 S Skerget (pgen.1011848.ref009) 2024; 56 EJ Wherry (pgen.1011848.ref032) 2007; 27 L Li (pgen.1011848.ref082) 2000; 191 VA Traag (pgen.1011848.ref097) 2019; 9 B Oben (pgen.1011848.ref012) 2021; 12 C Rébé (pgen.1011848.ref036) 2020; 12 KK Jovanović (pgen.1011848.ref020) 2018; 32 B Jäger (pgen.1011848.ref070) 2020; 73 |
| References_xml | – volume: 32 start-page: 1295 issue: 6 year: 2018 ident: pgen.1011848.ref020 article-title: Targeting MYC in multiple myeloma publication-title: Leukemia doi: 10.1038/s41375-018-0036-x – volume: 21 start-page: 691 issue: 3 year: 2007 ident: pgen.1011848.ref026 article-title: Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential publication-title: FASEB J doi: 10.1096/fj.06-6610com – volume: 23 start-page: 7627 issue: 14 year: 2022 ident: pgen.1011848.ref004 article-title: Targeting the microenvironment for treating multiple myeloma publication-title: Int J Mol Sci doi: 10.3390/ijms23147627 – volume: 129 start-page: 687 issue: 5 year: 2005 ident: pgen.1011848.ref069 article-title: Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2005.05507.x – volume: 22 start-page: 3490 issue: 7 year: 2021 ident: pgen.1011848.ref038 article-title: The role of CXCL16 in the pathogenesis of cancer and other diseases publication-title: Int J Mol Sci doi: 10.3390/ijms22073490 – volume: 3 start-page: 71 issue: 1 year: 2015 ident: pgen.1011848.ref081 article-title: HGF/c-MET axis in tumor microenvironment and metastasis formation publication-title: Biomedicines doi: 10.3390/biomedicines3010071 – volume: 11 start-page: 6077 issue: 1 year: 2020 ident: pgen.1011848.ref098 article-title: muscat detects subpopulation-specific state transitions from multi-sample multi-condition single-cell transcriptomics data publication-title: Nat Commun doi: 10.1038/s41467-020-19894-4 – volume: 167 start-page: 49 issue: 1 year: 2001 ident: pgen.1011848.ref083 article-title: The distinct roles of T cell-derived cytokines and a novel follicular dendritic cell-signaling molecule 8D6 in germinal center-B cell differentiation publication-title: J Immunol doi: 10.4049/jimmunol.167.1.49 – volume: 24 start-page: 1867 issue: 12 year: 2018 ident: pgen.1011848.ref014 article-title: Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma publication-title: Nat Med doi: 10.1038/s41591-018-0269-2 – volume: 33 start-page: 1063 issue: 5 year: 2019 ident: pgen.1011848.ref024 article-title: Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options publication-title: Leukemia doi: 10.1038/s41375-019-0404-1 – volume: 123 start-page: 25 year: 2015 ident: pgen.1011848.ref060 article-title: Role of inflammation in the aging bones publication-title: Life Sci doi: 10.1016/j.lfs.2014.11.011 – volume: 144 start-page: 76 issue: 1 year: 2006 ident: pgen.1011848.ref062 article-title: Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2006.03037.x – year: 2024 ident: pgen.1011848.ref102 article-title: A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma publication-title: bioRxiv – volume: 11 start-page: 694331 year: 2021 ident: pgen.1011848.ref072 article-title: Intratumor heterogeneity of MIF expression correlates with extramedullary involvement of multiple myeloma publication-title: Front Oncol doi: 10.3389/fonc.2021.694331 – volume: 12 start-page: 1791 issue: 7 year: 2020 ident: pgen.1011848.ref036 article-title: Interleukin-1β and cancer publication-title: Cancers (Basel) doi: 10.3390/cancers12071791 – volume: 19 start-page: 225 issue: 2 year: 2003 ident: pgen.1011848.ref042 article-title: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6 publication-title: Immunity doi: 10.1016/S1074-7613(03)00208-5 – volume: 103 start-page: 689 issue: 2 year: 2004 ident: pgen.1011848.ref035 article-title: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival publication-title: Blood doi: 10.1182/blood-2003-06-2043 – ident: pgen.1011848.ref051 doi: 10.1182/blood-2023-173550 – volume: 9 start-page: 5233 issue: 1 year: 2019 ident: pgen.1011848.ref097 article-title: From Louvain to Leiden: guaranteeing well-connected communities publication-title: Sci Rep doi: 10.1038/s41598-019-41695-z – start-page: 060012 year: 2016 ident: pgen.1011848.ref100 article-title: An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation publication-title: bioRxiv – volume: 14 issue: 5 year: 2018 ident: pgen.1011848.ref047 article-title: Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma publication-title: Asia Pac J Clin Oncol – volume: 20 start-page: 218 issue: 4 year: 2020 ident: pgen.1011848.ref044 article-title: CD8+ T cell states in human cancer: insights from single-cell analysis publication-title: Nat Rev Cancer doi: 10.1038/s41568-019-0235-4 – volume: 6 start-page: 5873 issue: 22 year: 2022 ident: pgen.1011848.ref016 article-title: Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level publication-title: Blood Adv doi: 10.1182/bloodadvances.2022007217 – volume: 31 start-page: 881 issue: 6 year: 2018 ident: pgen.1011848.ref027 article-title: Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms publication-title: Mod Pathol doi: 10.1038/s41379-018-0011-0 – volume: 136 start-page: 2557 issue: 22 year: 2020 ident: pgen.1011848.ref074 article-title: MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma publication-title: Blood doi: 10.1182/blood.2020005795 – volume: 17 start-page: 2331 issue: 11 year: 2019 ident: pgen.1011848.ref058 article-title: Proinflammatory macrophages promote multiple myeloma resistance to bortezomib therapy publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-19-0487 – volume: 12 start-page: 2559 issue: 1 year: 2021 ident: pgen.1011848.ref019 article-title: Co-evolution of tumor and immune cells during progression of multiple myeloma publication-title: Nat Commun doi: 10.1038/s41467-021-22804-x – volume: 27 start-page: 670 issue: 4 year: 2007 ident: pgen.1011848.ref032 article-title: Molecular signature of CD8+ T cell exhaustion during chronic viral infection publication-title: Immunity doi: 10.1016/j.immuni.2007.09.006 – volume: 5 start-page: 787 year: 2016 ident: pgen.1011848.ref085 article-title: Fam3c modulates osteogenic cell differentiation and affects bone volume and cortical bone mineral density publication-title: Bonekey Rep doi: 10.1038/bonekey.2016.14 – ident: pgen.1011848.ref050 doi: 10.1182/blood-2023-187755 – volume: 1806 start-page: 42 issue: 1 year: 2010 ident: pgen.1011848.ref037 article-title: CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer publication-title: Biochim Biophys Acta – volume: 9 start-page: 35 issue: 4 year: 2017 ident: pgen.1011848.ref080 article-title: Hepatocyte growth factor, a key tumor-promoting factor in the tumor microenvironment publication-title: Cancers (Basel) doi: 10.3390/cancers9040035 – volume: 397 start-page: 410 issue: 10272 year: 2021 ident: pgen.1011848.ref006 article-title: Multiple myeloma publication-title: Lancet doi: 10.1016/S0140-6736(21)00135-5 – volume: 27 start-page: 1739 issue: 12 year: 2011 ident: pgen.1011848.ref099 article-title: Molecular signatures database (MSigDB) 3.0 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btr260 – volume: 12 start-page: 173 issue: 1 year: 2020 ident: pgen.1011848.ref040 article-title: HB-EGF-EGFR signaling in bone marrow endothelial cells mediates angiogenesis associated with multiple myeloma publication-title: Cancers (Basel) doi: 10.3390/cancers12010173 – volume: 14 start-page: 865 issue: 9 year: 2017 ident: pgen.1011848.ref094 article-title: Simultaneous epitope and transcriptome measurement in single cells publication-title: Nat Methods doi: 10.1038/nmeth.4380 – volume: 100 start-page: 230 issue: 1 year: 2002 ident: pgen.1011848.ref063 article-title: Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6 publication-title: Blood doi: 10.1182/blood.V100.1.230 – volume: 93 start-page: 50 year: 2017 ident: pgen.1011848.ref084 article-title: Fam3c modulates osteogenic differentiation by down-regulating Runx2 publication-title: Differentiation doi: 10.1016/j.diff.2016.11.005 – volume: 15 issue: 12 year: 2014 ident: pgen.1011848.ref089 article-title: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70442-5 – ident: pgen.1011848.ref002 – volume: 26 start-page: 1115 year: 2021 ident: pgen.1011848.ref033 article-title: Dynamic regulatory networks of T cell trajectory dissect transcriptional control of T cell state transition publication-title: Mol Ther Nucleic Acids doi: 10.1016/j.omtn.2021.10.011 – volume: 5 start-page: 26 year: 2019 ident: pgen.1011848.ref021 article-title: Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma publication-title: J Cancer Metastasis Treat – volume: 1806 start-page: 208 issue: 2 year: 2010 ident: pgen.1011848.ref079 article-title: The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas publication-title: Biochim Biophys Acta – volume: 22 start-page: 3389 issue: 7 year: 2021 ident: pgen.1011848.ref086 article-title: Management of myeloma bone lesions publication-title: Int J Mol Sci doi: 10.3390/ijms22073389 – volume: 62 start-page: 377 issue: 2 year: 2021 ident: pgen.1011848.ref003 article-title: Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data publication-title: Leuk Lymphoma doi: 10.1080/10428194.2020.1827253 – volume: 22 start-page: 769 issue: 6 year: 2021 ident: pgen.1011848.ref017 article-title: The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape publication-title: Nat Immunol doi: 10.1038/s41590-021-00931-3 – volume: 16 start-page: 1289 issue: 12 year: 2019 ident: pgen.1011848.ref095 article-title: Fast, sensitive and accurate integration of single-cell data with Harmony publication-title: Nat Methods doi: 10.1038/s41592-019-0619-0 – year: 2018 ident: pgen.1011848.ref096 – volume: 9 start-page: 116 issue: 1 year: 2016 ident: pgen.1011848.ref048 article-title: T cells in multiple myeloma display features of exhaustion and senescence at the tumor site publication-title: J Hematol Oncol doi: 10.1186/s13045-016-0345-3 – volume: 133 start-page: 46 year: 2021 ident: pgen.1011848.ref061 article-title: The multifaceted roles of macrophages in bone regeneration: a story of polarization, activation and time publication-title: Acta Biomater doi: 10.1016/j.actbio.2021.04.052 – volume: 33 start-page: 495 issue: 5 year: 2015 ident: pgen.1011848.ref092 article-title: Spatial reconstruction of single-cell gene expression data publication-title: Nat Biotechnol doi: 10.1038/nbt.3192 – volume: 57 start-page: 1493 issue: 6 year: 2025 ident: pgen.1011848.ref013 article-title: Genomic landscape of multiple myeloma and its precursor conditions publication-title: Nat Genet doi: 10.1038/s41588-025-02196-0 – volume: 19 start-page: 15 issue: 1 year: 2018 ident: pgen.1011848.ref090 article-title: SCANPY: large-scale single-cell gene expression data analysis publication-title: Genome Biol doi: 10.1186/s13059-017-1382-0 – volume: 25 start-page: 1860 issue: 12 year: 2015 ident: pgen.1011848.ref093 article-title: Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells publication-title: Genome Res doi: 10.1101/gr.192237.115 – volume: 10 start-page: 3717 issue: 16 year: 2021 ident: pgen.1011848.ref043 article-title: Plasmacytoid dendritic cells in patients with MGUS and multiple myeloma publication-title: J Clin Med doi: 10.3390/jcm10163717 – volume: 8 issue: 4 year: 2019 ident: pgen.1011848.ref091 article-title: Scrublet: computational identification of cell doublets in single-cell transcriptomic data publication-title: Cell Syst – volume: 11 start-page: 529 issue: 4 year: 2019 ident: pgen.1011848.ref071 article-title: Role of macrophage Migration Inhibitory Factor (MIF) in melanoma publication-title: Cancers (Basel) doi: 10.3390/cancers11040529 – volume: 64 start-page: 422 issue: 6 year: 2014 ident: pgen.1011848.ref001 article-title: Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back publication-title: CA Cancer J Clin – volume: 19 start-page: 665 issue: 11 year: 2019 ident: pgen.1011848.ref030 article-title: Defining “T cell exhaustion” publication-title: Nat Rev Immunol doi: 10.1038/s41577-019-0221-9 – volume: 8 issue: 11 year: 2017 ident: pgen.1011848.ref059 article-title: BAFF is involved in macrophage-induced bortezomib resistance in myeloma publication-title: Cell Death Dis doi: 10.1038/cddis.2017.533 – volume: 22 start-page: 103 issue: 1 year: 2013 ident: pgen.1011848.ref025 article-title: Therapeutic targeting of c-KIT in cancer publication-title: Expert Opin Investig Drugs doi: 10.1517/13543784.2013.740010 – volume: 97 start-page: 1086 issue: 8 year: 2022 ident: pgen.1011848.ref005 article-title: Multiple myeloma: 2022 update on diagnosis, risk stratification, and management publication-title: Am J Hematol doi: 10.1002/ajh.26590 – volume: 38 start-page: 2380 issue: 21 year: 2020 ident: pgen.1011848.ref011 article-title: Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression publication-title: J Clin Oncol doi: 10.1200/JCO.20.00437 – volume: 2013 start-page: 183602 year: 2013 ident: pgen.1011848.ref052 article-title: Multiple myeloma macrophages: pivotal players in the tumor microenvironment publication-title: J Oncol doi: 10.1155/2013/183602 – volume: 108 issue: 11 year: 2016 ident: pgen.1011848.ref075 article-title: Role of myeloma-derived MIF in myeloma cell adhesion to bone marrow and chemotherapy response publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djw131 – volume: 6 start-page: 26826 issue: 29 year: 2015 ident: pgen.1011848.ref023 article-title: Notch signaling deregulation in multiple myeloma: a rational molecular target publication-title: Oncotarget doi: 10.18632/oncotarget.5025 – volume: 22 start-page: 802 issue: 7 year: 2021 ident: pgen.1011848.ref028 article-title: “Mind the GAP”: RGS1 hinders antitumor lymphocytes publication-title: Nat Immunol doi: 10.1038/s41590-021-00961-x – volume: 34 start-page: 3111 issue: 12 year: 2020 ident: pgen.1011848.ref007 article-title: Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) publication-title: Leukemia doi: 10.1038/s41375-020-01051-x – volume: 295 start-page: 2495 issue: 8 year: 2020 ident: pgen.1011848.ref088 article-title: Cell adhesion in cancer: Beyond the migration of single cells publication-title: J Biol Chem doi: 10.1074/jbc.REV119.007759 – volume: 99 start-page: 13009 issue: 20 year: 2002 ident: pgen.1011848.ref067 article-title: T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.202491499 – volume: 5 issue: 2 year: 2015 ident: pgen.1011848.ref054 article-title: B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? publication-title: Blood Cancer J doi: 10.1038/bcj.2015.3 – volume: 13 start-page: 7040 issue: 1 year: 2022 ident: pgen.1011848.ref018 article-title: Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis publication-title: Nat Commun doi: 10.1038/s41467-022-33944-z – volume: 56 start-page: 1878 issue: 9 year: 2024 ident: pgen.1011848.ref009 article-title: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes publication-title: Nat Genet doi: 10.1038/s41588-024-01853-0 – volume: 1 start-page: 493 issue: 5 year: 2020 ident: pgen.1011848.ref015 article-title: Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma publication-title: Nat Cancer doi: 10.1038/s43018-020-0053-3 – volume: 7 start-page: 82 issue: 1 year: 2019 ident: pgen.1011848.ref077 article-title: Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0551-y – volume: 8 start-page: 3 issue: 1 year: 2023 ident: pgen.1011848.ref049 article-title: Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma publication-title: NPJ Genom Med doi: 10.1038/s41525-022-00340-x – volume: 27 start-page: 439 issue: 2 year: 2010 ident: pgen.1011848.ref055 article-title: New targets of PS-341: BAFF and APRIL publication-title: Med Oncol doi: 10.1007/s12032-009-9230-z – volume: 2012 start-page: 397648 year: 2012 ident: pgen.1011848.ref065 article-title: Immunotherapy using dendritic cells against multiple myeloma: how to improve? publication-title: Clin Dev Immunol – volume: 12 start-page: 1861 issue: 1 year: 2021 ident: pgen.1011848.ref012 article-title: Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities publication-title: Nat Commun doi: 10.1038/s41467-021-22140-0 – volume: 17 start-page: 1133 issue: 8 year: 2011 ident: pgen.1011848.ref046 article-title: Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2011.03.011 – volume: 13 start-page: 3449 issue: 1 year: 2022 ident: pgen.1011848.ref010 article-title: Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes publication-title: Nat Commun doi: 10.1038/s41467-022-30694-w – volume: 4 start-page: 799 issue: 9 year: 2016 ident: pgen.1011848.ref076 article-title: Molecular programming of tumor-infiltrating CD8+ T cells and IL15 resistance publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-15-0178 – volume: 21 start-page: 799 issue: 11 year: 2022 ident: pgen.1011848.ref057 article-title: Macrophages as tools and targets in cancer therapy publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-022-00520-5 – volume: 101 start-page: 6122 issue: 16 year: 2004 ident: pgen.1011848.ref022 article-title: Illegitimate WNT signaling promotes proliferation of multiple myeloma cells publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0305855101 – volume: 128 start-page: 2241 issue: 18 year: 2016 ident: pgen.1011848.ref073 article-title: Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma publication-title: Blood doi: 10.1182/blood-2016-01-695395 – volume: 97 start-page: 568 issue: 6 year: 2016 ident: pgen.1011848.ref029 article-title: Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance publication-title: Eur J Haematol doi: 10.1111/ejh.12774 – volume: 10 issue: 4 year: 2022 ident: pgen.1011848.ref053 article-title: Tumor-associated macrophages in multiple myeloma: advances in biology and therapy publication-title: J Immunother Cancer – ident: pgen.1011848.ref101 doi: 10.1101/2023.06.13.544751 – volume: 132 start-page: 1689 issue: 16 year: 2018 ident: pgen.1011848.ref045 article-title: TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma publication-title: Blood doi: 10.1182/blood-2018-01-825265 – volume: 26 issue: 6 year: 2017 ident: pgen.1011848.ref087 article-title: Mechanisms of bone destruction in multiple myeloma publication-title: Eur J Cancer Care (Engl) – volume: 11 start-page: 12 issue: 1 year: 2022 ident: pgen.1011848.ref031 article-title: Increased TOX expression associates with exhausted T cells in patients with multiple myeloma publication-title: Exp Hematol Oncol doi: 10.1186/s40164-022-00267-0 – volume: 191 start-page: 1077 issue: 6 year: 2000 ident: pgen.1011848.ref082 article-title: Identification of a human follicular dendritic cell molecule that stimulates germinal center B cell growth publication-title: J Exp Med doi: 10.1084/jem.191.6.1077 – volume: 103 start-page: 3148 issue: 8 year: 2004 ident: pgen.1011848.ref056 article-title: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone publication-title: Blood doi: 10.1182/blood-2003-06-1984 – volume: 126 start-page: 1443 issue: 12 year: 2015 ident: pgen.1011848.ref068 article-title: Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing publication-title: Blood doi: 10.1182/blood-2015-01-623975 – volume: 13 start-page: 43 issue: 1 year: 2010 ident: pgen.1011848.ref039 article-title: Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer publication-title: Angiogenesis doi: 10.1007/s10456-010-9163-3 – volume: 6 start-page: 20 year: 2017 ident: pgen.1011848.ref041 article-title: Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era publication-title: Exp Hematol Oncol doi: 10.1186/s40164-017-0081-6 – volume: 180 start-page: 3655 issue: 6 year: 2008 ident: pgen.1011848.ref034 article-title: Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL publication-title: J Immunol doi: 10.4049/jimmunol.180.6.3655 – volume: 108 start-page: 2020 issue: 6 year: 2006 ident: pgen.1011848.ref008 article-title: The molecular classification of multiple myeloma publication-title: Blood doi: 10.1182/blood-2005-11-013458 – volume: 73 start-page: 109672 year: 2020 ident: pgen.1011848.ref070 article-title: CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer publication-title: Cell Signal doi: 10.1016/j.cellsig.2020.109672 – volume: 91 start-page: 107318 year: 2021 ident: pgen.1011848.ref078 article-title: Biological effects of IL-15 on immune cells and its potential for the treatment of cancer publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.107318 – volume: 23 start-page: 904 issue: 2 year: 2022 ident: pgen.1011848.ref066 article-title: Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions publication-title: Int J Mol Sci doi: 10.3390/ijms23020904 – volume: 51 start-page: 1 issue: 1 year: 2015 ident: pgen.1011848.ref064 article-title: Dendritic cell-based cancer immunotherapy against multiple myeloma: from bench to clinic publication-title: Chonnam Med J doi: 10.4068/cmj.2015.51.1.1 |
| SSID | ssj0035897 |
| Score | 2.482934 |
| Snippet | Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our... |
| SourceID | doaj proquest pubmed crossref |
| SourceType | Open Website Aggregation Database Index Database |
| StartPage | e1011848 |
| SubjectTerms | Aged CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - pathology Disease Progression Female Humans Immunophenotyping Macrophages - immunology Male Middle Aged Monoclonal Gammopathy of Undetermined Significance - genetics Monoclonal Gammopathy of Undetermined Significance - immunology Monoclonal Gammopathy of Undetermined Significance - pathology Multiple Myeloma - genetics Multiple Myeloma - immunology Multiple Myeloma - pathology Smoldering Multiple Myeloma - genetics Smoldering Multiple Myeloma - immunology Smoldering Multiple Myeloma - pathology Tumor Microenvironment - genetics Tumor Microenvironment - immunology |
| Title | Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/41056512 https://www.proquest.com/docview/3258565087 https://doaj.org/article/d8866f13a70c4a41a6da579aa9986488 |
| Volume | 21 |
| WOSCitedRecordID | wos001588430800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1553-7404 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0035897 issn: 1553-7404 databaseCode: DOA dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1553-7404 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0035897 issn: 1553-7404 databaseCode: M7P dateStart: 20050701 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1553-7404 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0035897 issn: 1553-7404 databaseCode: 7X7 dateStart: 20050701 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1553-7404 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0035897 issn: 1553-7404 databaseCode: BENPR dateStart: 20050701 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1553-7404 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0035897 issn: 1553-7404 databaseCode: PIMPY dateStart: 20050701 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1553-7404 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0035897 issn: 1553-7404 databaseCode: FPL dateStart: 20050701 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwEB7BAhIXxJvyqIzENWwT27F9ZNFWrLRUEQJUTtHEdlaVaFK1KVL_PWM7XS0HxIWLFeVla77E_kae-QbgneOlFl66rMhLmQnrRNYgd0TktMidMMrFynPfL9VioZdLU90o9RViwpI8cDLcqdO6LNuco5pZgSLH0qFUBtEEYXEd03yJ9RydqTQHc6lTWRUpeabIrR-T5rjKT0eM3m8IoOC7kouj_1iUonb_3wlnXHjmD-HByBjZhzTSR3DLd4_hXqoheXgCVxchwyOoA3T9cNisLEu5vDu26hixOzbs1_2WYefGo3UIwbuR38ZSpiKLkVpJpYMNPTtGGrL1wf_s1_gUvs3Pv378lI3VEzLL1WygyVVY9FgIbFviEXnpZtpK1Nxia5zxyoaKY760Hn2uG8ult6ZtjHWuyBtp-DM46frOvwBGr1DWNkHrzAmvJZa0qBlFbEMhPeQmkB3NV2-SSEYdd8oUORfJSnUwdz2aewJnwcbX9waJ63iCgK9H4Ot_AT-Bt0eEavolwj4Hdr7f72pekA8UmKeawPME3XVXIaq1JJLz8n8M4RXcL0I54Bjb9xpOhu3ev4G79tew2m2ncFstVWz1FO6cnS-qL9P4lVI7ry6nIcy0oivVxefqx2-M8e6- |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunophenotypic+changes+in+the+tumor+and+tumor+microenvironment+during+progression+to+multiple+myeloma&rft.jtitle=PLoS+genetics&rft.au=Bergiers%2C+Isabelle&rft.au=K%C3%B6se%2C+Murat+Cem&rft.au=Skerget%2C+Sheri&rft.au=Malfait%2C+Milan&rft.date=2025-10-01&rft.issn=1553-7404&rft.eissn=1553-7404&rft.volume=21&rft.issue=10&rft.spage=e1011848&rft_id=info:doi/10.1371%2Fjournal.pgen.1011848&rft.externalDBID=n%2Fa&rft.externalDocID=10_1371_journal_pgen_1011848 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1553-7404&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1553-7404&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1553-7404&client=summon |